Health · Medical Research · 1 hr ago
Drug combination cleared tumors and triggered lasting protection in mice
Researchers at Regeneron tested a cancer drug with an experimental antibody in mice with engineered breast or colorectal tumors.
The drug, Enhertu, carries a cell-killing payload to tumor cells with the HER2 protein, while the antibody is designed to help immune cells attack.
Together, the treatments cleared breast tumors in all nine mice that received them, compared with fewer than half responding to the drug alone at the highest tested dose.
After staying tumor-free for at least four weeks, the mice rejected the same breast cancer cells without more treatment.
They did not resist a different colorectal tumor that also carried HER2, suggesting their immune systems recognized other features of the original cancer.
Removing CD8 T cells eliminated the combination’s benefit, showing those cells were essential to the result.
The findings are from mice, while one experimental antibody is already in early-stage human trials; the study does not establish whether these combinations will work in people.
A cancer drug combined with an experimental antibody eliminated breast tumors in all nine treated mice in one test.
The mice later rejected another injection of the same cancer cells without further treatment.
The study’s researchers said CD8 T cells were essential to the initial combination’s benefit.
Other combinations also slowed or rejected tumors in mouse models of breast or colorectal cancer.
The findings are from animal tests and do not establish that the treatments work in people.
- Who
- Researchers at Regeneron Pharmaceuticals tested the treatments in mice.
- What
- They combined cancer drugs with experimental antibodies to treat tumors and assess whether the mice developed lasting protection.
- When
- The article was published on November 21, 2026. The mice were rechallenged after remaining tumor-free for at least four weeks.
- Where
- In engineered mouse models of breast and colorectal tumors. The researchers were at Regeneron Pharmaceuticals, a US biotechnology company.
- Why
- The researchers wanted to strengthen cancer treatment by helping the immune system join the attack.
This story does not have two clearly opposing sides.
Enhertu alone produced complete tumor responses in fewer than half the mice, while the combination eliminated tumors in all nine mice receiving both treatments.
After the mice had remained tumor-free, researchers injected them with the same breast cancer cells again, and the animals rejected them without further treatment.
- Combination
- Enhertu (trastuzumab deruxtecan) plus an experimental antibody
- Initial breast tumor test
- Tumors were eliminated in all 9 mice receiving both treatments
- Tumor rechallenge
- Same breast cancer cells were rejected after at least 4 weeks without further treatment
- EGFR-targeting antibody test
- Tumor rejection in about 75% of mice in a breast tumor model
- Immune cells
- Removing CD8 T cells abolished the initial combination’s benefit